Tag: "hemophilia" at medical news
One dose of 'designer' gene therapy may target specific body area
...from a single dose. This is based on results from hemophilia
studies from other laboratories in which the virus was used to deliver gene therapy. In these studies, Baker said that a single dose could last up to five years, possibly longer as the studies are ongoing. AAV is also a good choice because it does ...
FDA approves Baxters ADVATE for the treatment of hemophilia A
...on and control of bleeding episodes in people with hemophilia
A. ADVATE is the first and only factor VIII made ...hrough its innovative technology and many years in hemophilia
research, ADVATE is a genetically engineered, or recombinant, full-length clotting factor VIII that ...
Baxter introduces Baxject needleless transfer device at International Haemophilia Congress
...JECT device is compatible for use only with Baxter hemophilia
therapies and will be introduced globally during the next six months. Initially the BAXJECT device will be available with Recombinate (recombinant antihaemophilic factor) and will eventually replace the transfer needles currently included in all pac...
High turnover rate may undermine HIV/hemophilia care
...kers taking care of patients who have both HIV and hemophilia
is due more to stress from coworkers than to the h...loyee retention among those who work only with the hemophilia
patients, Brown says. The article is published in the February issue of General Hospital Psychiatry....
UNC physicians seeking patients for blood clot, medication studies
... While treatment centers for bleeding disorders in hemophilia
exist where different specialists work together, very few options exist for patients with thrombosis, he said. "We need to encourage Congress to fund centers in thrombophilia," Moll said. "Currently, no government-funded centers exist in this country...
Study evaluates dosage adjustments of Agenerase
...n reports of spontaneous bleeding in patients with hemophilia
A and B treated with protease inhibitors. The majority of adverse events were of mild to moderate intensity (grade 1-2), early to onset and transient. Treatment-limiting (grade 3-4) adverse events occurred in 5 percent or less of patients. The most...
Seattle researchers uncover structure of blood-clotting protein involved in most common form of hemophilia
...ture of a key blood-clotting protein implicated in hemophilia
A, the most prevalent and serious type of hemophil..., why factor VIII doesn't work in many people with hemophilia
A," says Stoddard, a member of the Hutchinson Center's Basic Sciences Division and an affiliate asso...
Vaccine against Hepatitis A protects kids and families now; Hepatitis B vaccine
protects kids as they become adults
...land bisexual men; and patients such as those with hemophilia
who receiveclotting factor. "Many people are understandably hesitant when they hear about new vaccines. Itseems like there's a new one every couple of months," says Dr. Lehman. "But inthe big picture, two shots for hepatitis A over six months is a mi...